Results 201 to 210 of about 39,473 (264)

Enhancements in morphology, biochemicals, nutrients, and L-Dopa in Faba bean through plant growth promoting rhizobacteria and arbuscular mycorrhizal Fungi. [PDF]

Sci Rep
Yilmaz H.
europepmc   +1 more source

L-DOPA Test in the Diagnosis of Childhood Short Stature: Evaluation of Growth Hormone Peaks Over Time. [PDF]

Endocrinol Diabetes Metab
Castelli B, De Santis R, Carrera S, Malanima MA, De Masi S, Stagi S.   +5 more
europepmc   +1 more source

Enhancement of Haloperidol-Induced Catalepsy by GPR143, an l-DOPA Receptor, in Striatal Cholinergic Interneurons. [PDF]

J Neurosci
Hatzipantelis CJ.
europepmc   +1 more source

Intrastriatal injection of alpha-synuclein preformed fibrils to rats results in L-DOPA reversible sensorimotor impairments and alterations in non-motor function. [PDF]

Front Neurosci
Fleming SM, Scott S, Hamad EJ, Herman DE, Holden JG, Yan L, Linning-Duffy K, Kemp CJ, Patterson JR, Miller KM, Kubik M, Kuhn N, Stoll AC, Duffy MF, Steece-Collier K, Cole-Strauss A, Lipton JW, Luk KC, Sortwell CE.   +18 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

L-Dopa and Oligozoospermia

Andrologia, 2009
A clinical investigation of L-Dopa on idiopathic oligozoospermia is carried out. Thirty nine male oligozoospermic patients with primary sterility were divided in two groups. The first group of 25 patients was treated with 500 mg a day during two months. The second group of 14 patients received 750 mg a day for the same time.
J C, Lavieri, A A, Pierini
openaire   +2 more sources

L-Dopa and Parkinsonism

Nature, 1970
This new treatment for an old disease has its origins in pharmacological research of the late 1950s. There is still not full agreement about how L-dopa functions in the nervous system, but, as this review shows, there is ample evidence to support the clinical work in progress since 1961.
D B, Calne, M, Sandler
openaire   +2 more sources

l-dopa and pancreatic secretion

Biochemical Pharmacology, 1973
Abstract Greengard , Roback and Ivy (1942) first observed that epinine ( N -methyldopamine), dopamine (dihydroxyphenylethylamine) and few phenylethylamine derivatives given intravenously stimulated the canine pancreatic secretion, while the majority of sympathomimetic amines tested inhibited it.
KOROKU HASHIMOTO, YASUHIKO FURUTA, KAZUHIKO IWATSUKI   +2 more
openaire   +1 more source

Antispastic effects of l-dopa

Experimental Brain Research, 1996
Antispastic effects of the noradrenaline and dopamine precursor l-3,4-dihydroxyphelanine (L-dopa) were investigated in 11 subjects in which exaggerated stretch reflexes developed after spinal cord injuries. The effects were evaluated from changes in the electromyographic (EMG) response of the quadriceps muscle during tendon jerks evoked by standardized
J, Eriksson, B, Olausson, E, Jankowska
openaire   +2 more sources

Electroenzymatic synthesis of l-DOPA

Journal of Biotechnology, 2010
Parkinson's disease is caused by a deficiency of the neurotransmitter dopamine. Since l-DOPA (l-3,4-dihydroxyphenylalanine) is a precursor of dopamine and can pass across the blood-brain barrier, it has been used as a treatment for Parkinson's disease.
Kyoungseon, Min, Don-Hee, Park, Young Je, Yoo   +2 more
openaire   +2 more sources

Effect of L‐Dopa on Polycythemia

Journal of the American Geriatrics Society, 1977
ABSTRACT A patient with Parkinson's disease, in whom polycythemia vera was known to be present for several years prior to the onset of parkinsonian symptoms, received treatment with a preparation consisting of L‐dopa plus a decarboxylase inhibitor (Madopar).
Y, Herishanu, P, Rosenberg
openaire   +2 more sources